Monitoring of osteoporosis therapy

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 6, 2014, Pages 835-841

  Bruyére, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bone mineral density; Bone turnover markers; Monitoring; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER;

ARTICLE; BONE DENSITY; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; TREATMENT RESPONSE; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ABSORPTIOMETRY, PHOTON; BIOLOGICAL MARKERS; BONE DENSITY; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84927972900     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.07.001     Document Type: Review

References (50)

1. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone 2008; 42: 467-75.
2. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2013; 24: 23-57.
3. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
4. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: A perspective. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2008; 23: 1155-67.
5. Compston J. Monitoring osteoporosis treatment. Best practice & research. Clin Rheumatol 2009; 23: 781-8.
6. Lewiecki EM. Monitoring pharmacological therapy for osteoporosis. Rev Endocr Metabolic Disord 2010; 11: 261-73.
7. Baum T, Karampinos DC, Liebl H, et al. High-resolution bone imaging for osteoporosis diagnostics and therapy monitoring using clinical MDCT and MRI. Curr Med Chem 2013; 20: 4844-52.
8. Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: Position paper of the International Society for Clinical Densitometry. J Clin Densitom Official J Int Soc Clin Densitom 2005; 8: 371-8.
9. Kolta S, Ravaud P, Fechtenbaum J, et al. Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2000; 11: 709-13.
10. Roux C, Garnero P, Thomas T, et al. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Jt Bone Spine Rev Du rhum 2005; 72: 26-31.
11. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA J Am Med Assoc 2000; 283: 1318-21.
12. Ravaud P, Reny JL, Giraudeau B, et al. Individual smallest detectable difference in bone mineral density measurements. J Bone Mineral Res Official J Am Soc Bone Mineral Res 1999; 14: 1449-56.
13. Bonnick SL. Monitoring osteoporosis therapy with bone densitometry: A vital tool or regression toward mediocrity? J Clin Endocrinol Metabolism 2000; 85: 3493-5.
14. Lenchik L, Watts NB. Regression to the mean: What does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom Official J Int Soc Clin Densitom 2001; 4: 1-4.
15. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-9.
16. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2002; 17: 1-10.
17. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metabolism 2002; 87: 1586-92.
18. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34: 599-604.
19. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone mineral Res Official J Am Soc Bone Mineral Res 2004; 19: 330-7.
20. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2012; 27: 687-93.
21. Detilleux J, Reginster JY, Chines A, et al. A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Stat Methods Med Res 2012. http://dx.doi.org/10.1177/0962280212456655. [Published online].
22. Bruyere O, Detilleux J, Chines A, et al. Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. Calcif Tissue Int 2012; 91: 244-9.
23. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA J Am Med Assoc 1999; 282: 1344-52.
24. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2000; 11: 83-91.
25. Chapurlat RD, Palermo L, Ramsay P, et al. Risk of fracture among women who lose bone density during treatment with alendronate. The fracture intervention trial. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2005; 16: 842-8.
26. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom Official J Int Soc Clin Densitom 2004; 7: 255-61.
27. Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2005; 20: 2097-104.
28. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metabolism 2007; 92: 3076-81.
29. Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatidetreated postmenopausal women with osteoporosis. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2006; 21: 1785-90.
30. Bruyere O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 2007; 23: 3041-5.
31. Reginster JY, Collette J, Neuprez A, et al. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008; 42: 832-6.
32. Seibel MJ. Biochemical markers of bone turnover: Part I: Biochemistry and variability. Clin Biochem Rev/Aust Assoc Clin Biochem 2005; 26: 97-122.
33. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2000; 11 (Suppl. 6) : S30-44.
34. Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club. Int J Clin Pract 2009; 63: 19-26.
35. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2011; 22: 391-420.
36. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with longterm changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metabolism 2005; 90: 2762-7.
37. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2005; 20: 962-70.
38. Funck-Brentano T, Biver E, Chopin F, et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: A systematic review. Seminars Arthritis Rheumatism 2011; 41: 157-69.
39. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2003; 18: 1051-6.
40. Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344-51.
41. Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Mineral Res Official J Am Soc Bone Mineral Res 2004; 19: 394-401.
42. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2008; 19: 811-8.
43. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metabolism 2004; 89: 1117-23.
44. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metabolism 2007; 92: 1296-304.
45. Silverman SL, Nasser K, Nattrass S, et al. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: A community setting-based trial. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2012; 23: 1069-74.
46. Roux C, Giraudeau B, Rouanet S, et al. Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Jt Bone Spine Rev Du rhum 2012; 79: 389-92.
47. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2000; 11: 533-6.
48. Rothman MS, Miller PD, Lewiecki EM, et al. Bone density testing: Science, the Media, and patient care. Curr Osteoporos Reports 2014; 12: 227-9.
49. Muncie Jr. HL, LeBlanc LL. Monitoring osteoporosis treatment: DXA should not be routinely repeated. Am Fam Physician 2010; 82: 749-54.
50. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int J Established as Result Coop between Eur Found Osteoporos Natl Osteoporos Found USA 2012; 23: 2769-74.